Your session is about to expire
← Back to Search
SABR vs EBRT for Prostate Cancer (ASSERT Trial)
ASSERT Trial Summary
This trialwill compare two radiation therapy techniques for prostate cancer. One is brachytherapy, an invasive treatment with excellent outcomes. The other is EBRT, more gentle but with poorer outcomes. SABR, with a few high dose treatments, is being tested for efficacy and safety.
ASSERT Trial Eligibility Criteria
Inclusion Criteria
You may be eligible if you check “Yes” for the criteria belowASSERT Trial Timeline
Treatment Details
Study Objectives
Outcome measures can provide a clearer picture of what you can expect from a treatment.ASSERT Trial Design
Find a Location
Who is running the clinical trial?
Media Library
- I can undergo hormone therapy for 6 or 18 months without health risks.My recent scans show no cancer spread in my pelvis or bones.My prostate cancer has spread beyond the prostate.I have a history of inflammatory bowel disease.I have had radiation therapy to my pelvic area before.My cancer is in an early stage (T1 or T2).I have had a prostate exam in the last 60 days or before starting hormone therapy.I am able to care for myself and perform daily activities.I have been cancer-free for at least 5 years, except for non-melanoma skin cancer.My cancer has spread to my pelvic nodes or further.I was diagnosed with prostate cancer in the last year.My prostate cancer is considered high or intermediate risk with a low chance of spread to pelvic nodes.I have started hormone therapy for my cancer.
- Group 1: SABR with androgen suppression
- Group 2: EBRT with androgen suppression
- All Individual Drugs Already Approved - Therapies where all constituent drugs have already been approved are likely to have better-understood side effect profiles.
- Approved for 5 Other Conditions - This treatment demonstrated efficacy for 5 other conditions.
- No Placebo-Only Group - All patients enrolled in this study will receive some form of active treatment.
- Screening: It may take up to 3 Weeks to process to see if you qualify in this trial.
- Treatment: The duration you will receive the treatment varies.
- Follow Ups: You may be asked to continue sharing information regarding the trial for 6 Months after you stop receiving the treatment.
Frequently Asked Questions
In what circumstances is SABR with androgen suppression typically employed?
"Radiotherapy is typically administered with SABR and hormone inhibition. In some cases, this technique may also be beneficial for palliative therapy, endometrial thinning, as well as uterine bleeding."
Are there any remaining vacancies for participants in this clinical research?
"According to the information found on clinicaltrials.gov, this investigation is no longer accepting participants; although it was initially posted on April 1st 2016 and updated last October 31st 2022. Nevertheless, 1389 other medical trials are enrolling volunteers presently."
What is the size of the sample population for this research initiative?
"Unfortunately, this study is not currently recruiting. The trial was first published on April 1st 2016 and the most recent update to its information occurred on October 31 2022. If you are in search of alternative studies, 1322 trials involving prostate cancer patients and 67 clinical trials concerning SABR with androgen suppression are presently looking for participants."
Is this the inaugural trial of its type?
"Since 2000, SABR with androgen suppression has been a focus for medical research. AstraZeneca initially sponsored the clinical trial in 2000 which involved 600 people. After successful completion of Phase 3 trials this therapy became approved as an official drug treatment option. Currently there are 67 active studies related to SABR with androgen suppression spanning 1327 cities over 50 nations worldwide."
Share this study with friends
Copy Link
Messenger